Apertura has entered a CRADA with various NIH institutes for a gene therapy to treat Niemann-Pick Disease Type C1 (NPC1).

Now, her ongoing alliance with a telehealth company may be signifying a broader shift in US healthcare advertising, reflecting a changing of the guard in celebrity endorsements. The 23-time Grand Slam ...

Bayer's agreement with Apollo comes a little after Bayer broke its pharma dealmaking fast by acquiring Perfuse Therapeutics in May 2026.

The funds will support the progression of MindRank’s pipeline, which is heavily dominated by obesity indications.

Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus to treat multiple sclerosis.

AstraZeneca and Sino Biopharmaceutical's subsidiary CTTQ have signed an exclusive licence agreement for TQC3721.

Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here?

Anthropic launches Claude Science as big tech companies increasingly eye expansion in the wider healthcare and life sciences space.

Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

The biotech’s potential launch on the public markets would help fuel development of its clinical-stage, melanocortin-focused pipeline.

Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.

Novo Nordisk has taken an interest in a weight-loss implant developed by Californian medtech Vivani Medical, reflecting a broadening of the drugmaker’s strategy to fend off mark ...